PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) is set to highlight its latest research in immunotherapy at several prestigious scientific conferences this October. These presentations will focus on INO-3107, a promising adjuvant immunotherapy for treating Recurrent Respiratory Papillomatosis (RRP), a rare disease caused by the human papillomavirus.
At the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy in Boston, Dr. Matthew Morrow, VP of Translational Sciences at INOVIO, will present a poster on October 19, 2024. His research will explore how INO-3107 reduces surgical interventions for RRP patients by enhancing immune cell signatures in the airways.
Dr. Michael Sumner, Chief Medical Officer at INOVIO, will deliver an oral presentation and poster at the ISV Congress 2024 in Seoul, Korea on October 22, 2024. His findings will delve into the clinical benefits of INO-3107 for adult RRP patients.
Further insights will be shared by Dr. Jeffrey Skolnik, SVP of Clinical Development at INOVIO, at the Fall Voice conference in Phoenix, AZ, from October 25-26, 2024. His poster presentation will also examine INO-3107’s therapeutic impact on RRP.
Finally, Dr. Dave Liebowitz, SVP of Early-Stage Clinical Development at INOVIO, will participate in a presentation and panel discussion at the World Vaccine Congress Europe in Barcelona, Spain, on October 28, 2024. He will discuss platform technologies in a pre-congress workshop, reflecting INOVIO’s commitment to advancing vaccine research.
These presentations highlight INOVIO’s efforts to pioneer immunotherapy solutions that address complex medical conditions. Abstracts will be accessible on the company’s website after each event, providing detailed insights into this groundbreaking research.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.